Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA flu and COVID-19 combination vaccine in healthy adults
NCT06821061Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of COVID-19 vaccine + influenza vaccine in influenza and coronavirus disease 2019 (COVID-19) (18 arms), sponsored by BioNTech SE. Primary endpoints: Percentage of participants reporting prompted local reactions at 7 days, Percentage of participants reporting prompted systemic events at 7 days and 2 more. Started Feb 2025; status: completed.
02
Drugs
COVID-19 vaccine + influenza vaccine
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06821061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821061.